Milagros Yunes, MD
Nephrology · Bronx, NYNPI 1295117810
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,685 of the $13,965 with a category attached, or 83.7%. Otsuka Pharmaceutical Development & Commercialization, Inc. accounts for 70.2% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $6,807 and has fallen 97.8% since, to $150 in 2025. Among nephrology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 36 payments — averaging $387.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$10K
- Otsuka America Pharmaceutical, Inc.$4K
- Boston Scientific$178
- Amgen$75
- Bayer$59
- Ardelyx, Inc.$40
- plus $18 from 1 others
What the payments were for
- Consulting fees$11,68584%
- Travel & lodging$1,65412%
- Food & beverage$6264%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 8 | $9,802 |
| Otsuka America Pharmaceutical, Inc. | 19 | $3,793 |
| Boston Scientific | 1 | $178 |
| Amgen | 3 | $75 |
| Bayer | 2 | $59 |
| Ardelyx, Inc. | 2 | $40 |
| Akebia Therapeutics Inc | 1 | $18 |
How this compares
$13,965 in reported general payments places this provider in the 90th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 20 | $48,707 |
| JardianceEmpagliflozin | 17 | $18,718 |
| FarxigaDapagliflozin Propanediol | 11 | $9,769 |
| Nifedipine ErNifedipine | 29 | $534 |
| Metoprolol Succinate | 20 | $198 |
| Atorvastatin Calcium | 11 | $135 |
| Furosemide | 30 | $78 |
| Losartan Potassium | 26 | $68 |
| Torsemide | 11 | $36 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Bronx
- Bruce SpinowitzBronx$465K
- Joel NeugartenBronx$248K
- Enver AkalinBronx$101K
- John KangBronx$93K
- Daniel AddankiBronx$54K
- Chaim CharytanBronx$34K
- Payam ShakouriPoughkeepsie$930K
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Steven CocaNew York$445K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.